Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers (Q42450983)

31 October 2017

Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers (English)

1 reference

31 October 2017

Mitsuya Itoh

1

1 reference

31 October 2017

Takayuki Iwamoto

2

1 reference

31 October 2017

Junji Matsuoka

3

1 reference

31 October 2017

Tomohiro Nogami

4

1 reference

31 October 2017

Takayuki Motoki

5

1 reference

31 October 2017

Tadahiko Shien

6

1 reference

31 October 2017

Naruto Taira

7

1 reference

31 October 2017

Naoki Niikura

8

1 reference

31 October 2017

Naoki Hayashi

9

1 reference

31 October 2017

Shoichiro Ohtani

10

1 reference

31 October 2017

Kenji Higaki

11

1 reference

31 October 2017

Toshiyoshi Fujiwara

12

1 reference

31 October 2017

Hiroyoshi Doihara

13

1 reference

31 October 2017

W Fraser Symmans

14

1 reference

31 October 2017

Lajos Pusztai

15

1 reference

31 October 2017

language of work or name

English

0 references

publication date

15 December 2013

1 reference

Breast Cancer Research and Treatment

31 October 2017

1 reference

31 October 2017

143

1 reference

31 October 2017

2

1 reference

31 October 2017

403-409

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-013-2763-z

31 October 2017

0 references

cites work

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Genomic index of sensitivity to endocrine therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2763-Z

10.1007/S10549-013-2763-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 October 2017

0 references

1 reference